Received Oct 10, 2025
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| MENB | MENINGOCOCCAL B (BEXSERO) | NOVARTIS VACCINES AND DIAGNOSTICS | 1 | DD72H | — |
| MENB | MENINGOCOCCAL B (TRUMENBA) | PFIZER\WYETH | 2 | — | — |
Interchangeability/Dosing Schedule (BEXSERO 1st dose, TRUMEMBA 2nd dose); This non-serious case was reported by a nurse via call center representative and described the occurrence of interchange of vaccine products in a 17-year-old female patient who received Men B NVS (Bexsero) (batch number DD72H) for prophylaxis. Co-suspect products included Meningococcal vaccine B rfHbpA/fHbpB (Trumenba) for prophylaxis. On 10-FEB-2025, the patient received the 1st dose of Bexsero. On 18-SEP-2025, the patient received the 2nd dose of Trumenba. On an unknown date, an unknown time after receiving Bexsero and Trumenba, the patient experienced interchange of vaccine products (Verbatim: Interchangeability/Dosing Schedule (BEXSERO 1st dose, TRUMEMBA 2nd dose)). The outcome of the interchange of vaccine products was not applicable. This report is made by GSK without prejudice and does not imply any admission or liability for the incident or its consequences. Additional Information: GSK Receipt Date: 23-SEP-2025 The first dose administered was Bexsero and received a Trumenba dose afterwards. The reporter asked how long do they have to wait to complete the series with Bexsero? The reporter consented to follow up.